Quantcast

Latest Benignity Stories

2014-07-09 23:10:19

NYC chiropractor Dr. Steven Shoshany is proud to now offer the Epley maneuver (also known as the Epley's Maneuver) for treating Benign Paroxysmal Positional Vertigo (BPPV) at his Manhattan integrated practice. New York, NY (PRWEB) July 09, 2014 Dr. Steven Shoshany, a New York City-based chiropractor, has been treating patients with back, neck and wrist pain for over fourteen years. However, as a chiropractor, he is not limited to treating injuries and disorders of the spine, but can...

2013-08-28 23:00:19

The Diamond Valley Brain Centre in Melbourne Australia has produced a series of informative graphics about the three most common causes of vertigo, BPPV, Meniere’s Disease and Vestibular Neuritis. The graphics will help patients, clinicians and health science students get a clear understanding of these common conditions. Melbourne, Australia (PRWEB) August 29, 2013 The Diamond Valley Brain Centre in Melbourne, Australia today highlighted its infographic series that it produced to help...

2012-04-23 22:02:53

University of Colorado School of Medicine researcher devises new exercise that allows the patient to 'self apply' A CU School of Medicine researcher who suffers from benign paroxysmal positional vertigo (BPPV) and had to "fix it" before she could go to work one day was using a maneuver to treat herself that only made her sicker. "So I sat down and thought about it and figured out an alternate way to do it. Then I fixed myself and went in to work" and discovered a new treatment for this...

2010-09-30 08:07:00

MINNETONKA, Minn., Sept. 30 /PRNewswire/ -- American Medical Systems® (AMS) (Nasdaq: AMMD), a leading provider of world-class devices and therapies for male and female pelvic health, today announced the worldwide launch of its revolutionary MoXy(TM) Liquid Cooled Fiber for laser treatment of benign prostatic hyperplasia (BPH) or enlarged prostate. Designed to be used with the recently launched GreenLight XPS(TM) (Xcelerated Performance System) 180 Watt laser, the MoXy...

2010-02-16 08:30:00

WALTHAM, Mass., Feb. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to longer than expected clinical development as well as competition from emerging novel injectable agents for the treatment of benign prostatic hyperplasia, Allergan's Botox will garner less market share than had been previously forecasted in the United States, France, Germany, Italy, Spain, the United Kingdom and...

2010-01-06 07:00:00

WALTHAM, Mass., Jan. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that GlaxoSmithKline's Duodart (the fixed-dose combination of dutasteride and tamsulosin) will earn Decision Resources' proprietary clinical gold standard status in 2013 and through 2018 for the treatment of benign prostatic hyperplasia/male lower urinary tract symptoms due to its competitive advantage in overall efficacy over...

2009-08-27 06:30:00

SEATTLE, Aug. 27 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company will hold an Analyst Day on Thursday, September 24, 2009 beginning at 8:45 a.m. ET. A live audio webcast of the presentation will be accessible through the Investor Relations section of the Dendreon website, http://www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the...

2009-08-03 07:00:00

WALTHAM, Mass., Aug. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2013 to 2018, generic erosion of established agents--most notably tamsulosin--will cause a decline of more than eight percent in the drug market for benign prostatic hyperplasia and male lower urinary tract symptoms in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Generic erosion will...

2008-10-10 09:00:19

Watson Pharmaceuticals, a specialty pharmaceutical company, has received the FDA approval for Rapaflo, the company's new alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia. The approval is based on data from two Phase III, 12-week, randomized, double-blind, placebo-controlled, multi-center studies as well as a 40 week open label study. In the two Phase III studies, 923 patients (mean age 64.6 years) were randomized to receive either Rapaflo 8mg...

2008-07-15 09:01:35

BELLEVUE, Wash., July 15 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO), a privately held company developing Light Infusion Therapy(TM) (Litx(TM)) to treat cancer and other conditions, today announced that it has raised $40.1 million in a Series C round of financing. The company raised $97 million in its first two rounds of financing. Investor names were not disclosed. LSO plans to use the funds in the continued development of Light Infusion Therapy (Litx), which includes two ongoing...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related